Idioma:

Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

Karikari, Thomas K ; Ashton, Nicholas J ; Brinkmalm, Gunnar ; Brum, Wagner S ; Benedet, Andréa L ; Montoliu-Gaya, Laia ; Lantero-Rodriguez, Juan ; Pascoal, Tharick Ali ; Suárez-Calvet, Marc ; Rosa-Neto, Pedro ; Blennow, Kaj ; Zetterberg, Henrik

Nature reviews. Neurology, 2022-07, Vol.18 (7), p.400-418 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Autor: Karikari, Thomas K ; Ashton, Nicholas J ; Brinkmalm, Gunnar ; Brum, Wagner S ; Benedet, Andréa L ; Montoliu-Gaya, Laia ; Lantero-Rodriguez, Juan ; Pascoal, Tharick Ali ; Suárez-Calvet, Marc ; Rosa-Neto, Pedro ; Blennow, Kaj ; Zetterberg, Henrik
Assuntos: Autopsies ; Biochemistry ; Biomarkers ; Biomedical research ; Brain research ; cerebrospinal-fluid ; Dementia ; diagnostic ; Laboratories ; Medical imaging ; mild cognitive impairment ; national institute ; Neurochemistry ; Neurodegeneration ; Neuroimaging ; Neurologi ; Neurology ; Neuropathology ; Neurosciences ; Neurosciences & Neurology ; p-tau ; paired helical filament ; Pathophysiology ; Phosphorylation ; phosphorylation sites ; plasma tau ; Primary care ; Proteins ; Psychiatry ; tau ; traumatic brain-injury
É parte de: Nature reviews. Neurology, 2022-07, Vol.18 (7), p.400-418
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Well-authenticated biomarkers can provide critical insights into the biological basis of Alzheimer disease (AD) to enable timely and accurate diagnosis, estimate future burden and support therapeutic trials. Current cerebrospinal fluid and molecular neuroimaging biomarkers fulfil these criteria but lack the scalability and simplicity necessary for widespread application. Blood biomarkers of adequate effectiveness have the potential to act as first-line diagnostic and prognostic tools, and offer the possibility of extensive population screening and use that is not limited to specialized centres. Accelerated progress in our understanding of the biochemistry of brain-derived tau protein and advances in ultrasensitive technologies have enabled the development of AD-specific phosphorylated tau (p-tau) biomarkers in blood. In this Review we discuss how new information on the molecular processing of brain p-tau and secretion of specific fragments into biofluids is informing blood biomarker development, enabling the evaluation of preanalytical factors that affect quantification, and informing harmonized protocols for blood handling. We also review the performance of blood p-tau biomarkers in the context of AD and discuss their potential contexts of use for clinical and research purposes. Finally, we highlight outstanding ethical, clinical and analytical challenges, and outline the steps that need to be taken to standardize inter-laboratory and inter-assay measurements.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility

Karikari, Thomas K ; Ashton, Nicholas J ; Brinkmalm, Gunnar ; Brum, Wagner S ; Benedet, Andréa L ; Montoliu-Gaya, Laia ; Lantero-Rodriguez, Juan ; Pascoal, Tharick Ali ; Suárez-Calvet, Marc ; Rosa-Neto, Pedro ; Blennow, Kaj ; Zetterberg, Henrik

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.